Loading
A phase 2 trial of Pembrolizumab, Belzutifan and Lenvatinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) is a phase 2 interventional study registered as NCT04976634 by Merck Sharp & Dohme LLC, with 730 participants enrolled, started 2021-08-18 and due to reach its primary completion in 2027-03-22. Interventions recorded: Pembrolizumab, Belzutifan and Lenvatinib.
Shares Belzutifan, Lenvatinib, Anti-angiogenic therapy, Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.